ZYNE Zynerba Pharmaceuticals, Inc.

+0.00  (0%)
Previous Close 7.30
Open 7.30
Price To book 1.86
Market Cap 67.15M
Shares 9,199,000
Volume 112,586
Short Ratio 5.08
Av. Daily Volume 201,943

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 to be initiated 2H 2017.
Phase 2 to be initiated 2H 2017.
Peripheral Neuropathic Pain (PNP)
Phase 2 trial initiation announced January 3, 2017. Data are due 3Q 2017.
Fragile X syndrome
Phase 2 initiated September 2016. Data are due July or August 2017 (following epilepsy data).
Phase 2 dosing commenced August 2016. Data are due July or August 2017.
ZYN002 - STAR 1
Adult Epilepsy Patients with Refractory Focal Seizures

Latest News

  1. Zynerba reports 1Q loss
  2. Zynerba Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational Highlights
  3. ETFs with exposure to Zynerba Pharmaceuticals, Inc. : May 8, 2017
  4. Yikes! These 5 Marijuana Stocks Lost a Combined $193 Million in 2016
  5. Implied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options
  6. ETFs with exposure to Zynerba Pharmaceuticals, Inc. : April 5, 2017
  7. Zynerba Pharmaceuticals, Inc. :ZYNE-US: Earnings Analysis: 2016 By the Numbers : March 29, 2017
  8. Edited Transcript of ZYNE earnings conference call or presentation 27-Mar-17 12:30pm GMT
  9. Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Operational Highlights
  10. Cannabis Space Continues To Shine As Latest IPO Therapix BioSciences (TRPX) Oversubscribed
  11. Agile Therapeutics (AGRX) Catches Eye: Stock Moves Up 14%
  12. Zynerba Pharmaceuticals to Report Fourth Quarter and Full-Year 2016 Financial and Operating Results on March 27, 2017
  13. Zynerba Pharmaceuticals Announces Completion of Enrollment for ZYN002 in Two Phase 2 Clinical Trials for Epilepsy and Osteoarthritis
  14. Emerging Cannabis Industry Presents Big Opportunities For Investors
  15. Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
  16. Zynerba Pharmaceuticals (ZYNE) Shares March Higher, Can It Continue?
  17. Patterson Companies (PDCO) Q3 Earnings: What's in Store?
  18. Medtronic (MDT) Q3 Earnings: Disappointment in the Cards?